Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

M K Hayden; K Rezai; R A Hayes; K Lolans; J P Quinn; R A Weinstein

doi:10.1128/JCM.43.10.5285-5287.2005

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

J Clin Microbiol. 2005 Oct;43(10):5285-7. doi: 10.1128/JCM.43.10.5285-5287.2005.

Authors

M K Hayden¹, K Rezai, R A Hayes, K Lolans, J P Quinn, R A Weinstein

Affiliation

¹ Rush University Medical Center, Chicago, IL 60612, USA. mhayden@rush.edu

Abstract

Daptomycin is a new lipopeptide antibiotic that is rapidly bactericidal against Staphylococcus aureus. We report daptomycin resistance and treatment failure in 2 patients with osteomyelitis due to methicillin-resistant S. aureus. Disk diffusion susceptibility testing failed to detect resistance. Daptomycin at high concentration retained bactericidal activity against resistant isolates.

Publication types

Case Reports

MeSH terms

Aged
Aged, 80 and over
Anti-Bacterial Agents / pharmacology*
Anti-Bacterial Agents / therapeutic use
Bacteremia / microbiology
Daptomycin / pharmacology*
Drug Resistance, Bacterial*
Female
Humans
Lumbar Vertebrae / microbiology
Lumbosacral Region / microbiology
Methicillin Resistance*
Microbial Sensitivity Tests / methods
Middle Aged
Osteomyelitis / microbiology
Staphylococcal Infections / microbiology
Staphylococcus aureus / drug effects*
Treatment Failure

Substances

Anti-Bacterial Agents
Daptomycin